1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Suven Life Sciences Limited

Suven Life Sciences Limited

SUVEN.NS
Suven Life Sciences LimitedIN flagNational Stock Exchange of India
357.00
INR
+10.25
- -
79.97BMarket Cap
Suven Life Sciences Limited
SUVEN.NS
(National Stock Exchange of India)

Recent

price

357.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
11.88
16.12
20.35
40.25
39.92
36.16
38.97
44.35
19.97
1.04
0.98
0.88
0.62
0.54
0.31
0.31
0.32
Revenue per Share
0.81
1.13
2.43
11.37
8.33
5.2
6.31
8.95
-1.73
-6.82
-5.22
-9.05
-5.42
-4.82
-7.37
-12.13
-12.42
Basic EPS, GAAP
0.09
0.51
0.84
6.57
1.89
0.7
5.69
2.04
-6.68
-9.92
-7.41
-10.93
-5.45
-3.79
-8.77
-13.47
- -
Free Cash Flow per Basic Share
0.27
0.27
0.32
0.32
2.62
2.88
0.92
1.66
1.67
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.92
0.92
0.92
13.24
20.17
20.54
24.88
31.05
6.17
-0.67
-5.92
-15
-14.35
-19.17
-26.54
1.16
1.19
Book Value per Share
10
10.07
12.19
20.86
43.18
43.07
48.2
55.36
17.31
10.37
7.81
7.12
17.2
12.37
5.03
25.95
26.57
Tangible Book Value per Share
127
127
127
127
130
138
138
138
138
138
138
135
218
218
218
228
223
Basic Weighted Avg Shares
1,504
2,042
2,579
5,103
5,209
4,995
5,382
6,126
2,758
144
135
118
135
117
67
71
71
Sales/Revenue/Turnover
-97.84
8.61
17.57
41.19
28.64
12.08
20.24
28.92
-8.99
-828.1
-616.99
-1,064.46
-974.35
-1,148.52
-2,578.13
-4,077.7
-4,077.7
Operating Margin (%)
79
85
105
115
242
240
276
248
142
40
35
36
58
58
53
56
56
Depreciation Expense
102
144
308
1,442
1,088
718
872
1,237
-239
-942
-722
-1,220
-1,183
-1,051
-1,607
-2,763
-2,763
Net Income, GAAP
- -
- -
6.13
28.89
28.24
26.37
29.16
36.74
15,423.14
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.8
7.03
11.96
28.25
20.88
14.38
16.2
20.19
-8.67
-653.62
-535.31
-1,029.99
-873.52
-898.62
-2,415.11
-3,884.13
-3,884.13
Profit Margin (%)
336
42
295
1,255
3,309
3,170
3,731
4,480
2,413
395
868
583
2,405
2,432
520
5,158
5,158
Working Capital
349
550
642
377
594
416
259
22
18
40
27
16
6
- -
- -
- -
- -
LT Debt
1,267
1,275
1,545
2,644
5,637
5,953
6,670
7,674
2,391
1,433
1,080
961
3,753
2,700
1,100
5,914
5,914
Total Equity
- -
- -
18.83
51.79
21.39
6.59
10.9
14.56
728.13
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
31.92
87.95
36.7
20.34
23.02
28.6
-75.48
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
87.98
123.04
264.08
160.58
50.46
26.27
27.79
32.02
-9.3
- -
- -
- -
- -
- -
- -
- -
-951.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
167
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
227
- -
264
Market Capitalization
44,749
36,663
29,309

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,782
- -
5,467
Cash, Cash Equivalents & STI
2,585
- -
5,218
Accounts Receivable, Net
11
- -
15
Inventories
2
- -
1
Total Current Liabilities
544
- -
309
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
167
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
52.33%
125.95%
437.7%
Free Cash Flow
43.31%
37.23%
60.35%
Net Income, GAAP
39.44%
35.95%
71.91%
Sales/Revenue/Turnover
-18.23%
-9.53%
6.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
31
25
24
117
2025
10
26
16
15
67
2026
19
9
28
15
71

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.1
-0.58
-1.92
- -
-4.82
2025
-1.29
-2.27
-1.79
-2.02
-7.37
2026
-2.36
-3.48
-4.55
-2.02
-12.13

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Greenrose Acquisition Corp. (GNRSW)
Chemesis International Inc. (CADMD)
Sentry Petroleum Ltd (SPLM)
4Front Ventures Corp. (FFNT.CN)
OptiNose, Inc. (OPTN)
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
Business
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company incorporated in 1989 and headquartered in Hyderabad, India, engages in the discovery, development, and commercialization of novel therapeutics targeting neurodegenerative disorders, with a primary focus on central nervous system (CNS) therapies including molecules for cognitive impairments such as Alzheimer's disease, dementia, narcolepsy, and delirium. The company provides comprehensive drug discovery and development support services to global pharmaceutical and biotechnology firms; offers contract research and manufacturing services encompassing synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME studies, pharmacology, toxicology, and clinical supplies manufacturing including formulations like tablets, capsules, injectables, and ophthalmics; and develops new chemical entities (NCEs) alongside generic product development, novel drug delivery systems (NDDS), and regulatory management. Operations span India with state-of-the-art facilities in Hyderabad and export activities to international markets including North America and Europe. In recent developments, the company pursues strategic fundraising through warrants issuance closed in July 2025 involving investors such as Jasti Family Trust, Quant Mutual Fund, and others; advances a merger with Suven Pharmaceuticals (rebranded as Cohance Lifesciences) approved by NCLT in March 2025 to create a technology-driven contract development and manufacturing organization (CDMO) platform across antibody drug conjugates, oligonucleotides, and small molecules, targeting over $1 billion in revenue within five years; and supports related expansions through acquisitions like Sapala Organics in June 2024 for oligonucleotide capabilities and NJ Bio in December 2024 for antibody-drug conjugate development.